ALTOR BIOSCIENCE CORPORATION

Company Information

Company Name
ALTOR BIOSCIENCE CORPORATION
Address
2810 N COMMERCE PKY
MIRAMAR, FL, 33025-3958
Phone
n/a
URL
n/a
DUNS
138254896
Number of Employees
n/a
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N

Award Totals

PROGRAM/PHASE
AWARD AMOUNT ($)
NUMBER OF AWARDS
SBIR Phase I
$951,616.00
4
SBIR Phase II
$5,883,720.00
3

Award List

  1. Novel IL-15 Superagonist Therapy for Bladder Cancer

    Amount: $225,279.00

    DESCRIPTION (provided by applicant): Non-Muscle Invasive Bladder cancer (NMIBC), the fifth most common cancer in the United States and the costliest to treat per patient of all cancers, tends to r ...

    SBIR Phase I 2011 Department of Health and Human Services
  2. Tissue Factor Antagonists for ALI/ARDS

    Amount: $3,187,074.00

    DESCRIPTION (provided by applicant): The pathogenesis of ALI/ARDS involves both procoagulant and inflammatory mechanisms. Extravascular fibrin deposition in the lung is a characteristic pathologic fe ...

    SBIR Phase II 2011 Department of Health and Human Services
  3. Evaluating Relevant Vaccine Epitopes Displayed on HIV-Infected Cells

    Amount: $237,181.00

    DESCRIPTION (provided by applicant): The HIV/AIDS pandemic continues to wreak havoc on global scale and has become one of the most destructive pandemics in recorded history. Despite the tremendous imp ...

    SBIR Phase I 2011 Department of Health and Human Services
  4. IL-15 Superagonist Complex as an Immunotherapeutic for Multiple Myeloma

    Amount: $231,853.00

    DESCRIPTION (provided by applicant): Multiple myeloma (MM) is the second most commonly diagnosed hematologic malignancy with an estimated 20,520 newly diagnosed cases and 10,610 deaths due to MM in t ...

    SBIR Phase I 2012 Department of Health and Human Services
  5. CD20-targeted IL-15 immunotherapeutic for B-cell malignancies

    Amount: $257,303.00

    DESCRIPTION (provided by applicant): Non-Hodgkin lymphoma (NHL) represents a significant clinical challenge in cancer management. Approximately 70,000 new cases of NHL are diagnosed annually in the U. ...

    SBIR Phase I 2012 Department of Health and Human Services
  6. Novel IL-15 Superagonist Therapy for Bladder Cancer

    Amount: $1,196,646.00

    DESCRIPTION (provided by applicant): Bladder cancer is the fifth most common cancer in the United States. Over 70 - 80% of patients initially present with non-muscle invasive bladder cancer (NMIBC) c ...

    SBIR Phase II 2014 Department of Health and Human Services
  7. IL-15 Superagonist Complex as an Immunotherapeutic for Multiple Myeloma

    Amount: $1,500,000.00

    DESCRIPTION (provided by applicant): Multiple myeloma (MM) is the second most commonly diagnosed hematologic malignancy with an estimated 22,350 newly diagnosed cases and 10,710 deaths due to MM in t ...

    SBIR Phase II 2014 Department of Health and Human Services

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government